Last reviewed 2026-05-27 · How we verify

VET3-TGI

KaliVir Immunotherapeutics · Phase 1 active Small molecule ✓ Verified May 2026

VET3-TGI is a Small molecule drug developed by KaliVir Immunotherapeutics. It is currently in Phase 1 development.

VET3-TGI is being studied in a Phase 1/1b clinical trial for the treatment of various types of solid tumors, including microsatellite stable colorectal cancer, head and neck squamous cell carcinoma, cervical cancer, and kidney cancer. In this trial, VET3-TGI is being investigated both as a standalone treatment and in combination with the immunotherapy drug atezolizumab.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VET3-TGI
Sponsor	KaliVir Immunotherapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of VET3-TGI in Patients With Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VET3-TGI CI brief — competitive landscape report
VET3-TGI updates RSS · CI watch RSS
KaliVir Immunotherapeutics portfolio CI

Frequently asked questions about VET3-TGI

What is VET3-TGI?

VET3-TGI is a Small molecule drug developed by KaliVir Immunotherapeutics.

Who makes VET3-TGI?

VET3-TGI is developed by KaliVir Immunotherapeutics (see full KaliVir Immunotherapeutics pipeline at /company/kalivir-immunotherapeutics).

What development phase is VET3-TGI in?

VET3-TGI is in Phase 1.

Manufacturer: KaliVir Immunotherapeutics — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing